Epidermal barrier reaction to an in vitro psoriatic microenvironment

Lynley, 1983, The characterization of human epidermal filaggrin. A histidine-rich, keratin filament-aggregating protein, Biochim. Biophys. Acta, 744, 28, 10.1016/0167-4838(83)90336-9 Bäsler, 2016, The role of tight junctions in skin barrier function and dermal absorption, J. Control Release, 242, 105, 10.1016/j.jconrel.2016.08.007 Brandner, 2015, Epidermal tight junctions in health and disease, Tissue Barriers, 3, e974451, 10.4161/21688370.2014.974451 Miller, 2008, Toll-like receptors in skin, Adv. Dermatol., 24, 71, 10.1016/j.yadr.2008.09.004 Kaisho, 2006, Toll-like receptor function and signalling, J. Allergy Clin. Immunol., 117, 979, 10.1016/j.jaci.2006.02.023 Kawai, 2010, The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors, Nat. Immunol., 11, 373, 10.1038/ni.1863 Jacobs, 1998, Structure of an IkappaBalpha/NF-kappaB complex, Cell, 95, 749, 10.1016/S0092-8674(00)81698-0 Goldminz, 2013, NF-κB: an essential transcription factor in psoriasis, J. Dermatol. Sci., 69, 89, 10.1016/j.jdermsci.2012.11.002 Hari, 2010, Toll-like receptors: role in dermatological disease, Mediat. Inflamm., 2010, 1, 10.1155/2010/437246 Gilliet, 2004, Psoriasis triggered by Toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors, Arch. Dermatol., 140, 1490, 10.1001/archderm.140.12.1490 Chen, 2016, Toll-like receptor pathways in autoimmune diseases. Clinic, Rev. Allerg. Immunol., 50, 1, 10.1007/s12016-015-8473-z Curry, 2003, Innate immune-related receptors in normal and psoriatic skin, Arch. Pathol. Lab. Med., 127, 178, 10.5858/2003-127-178-IIRRIN Donetti, 2005, Early epidermal response after a single dose of gamma-rays in organotypic culture of human breast skin, Br. J. Dermatol., 153, 881, 10.1111/j.1365-2133.2005.06804.x Donetti, 2014, An innovative three-dimensional model of normal human skin to study the pro-inflammatory psoriatic effects of tumor necrosis factor-alpha and interleukin-17, Cytokine, 68, 1, 10.1016/j.cyto.2014.03.003 Prignano, 2015, Tumour necrosis factor-alpha and interleukin-17 differently affects Langerhans cell distribution and activation in an innovative three-dimensional model of normal human skin, Eur. J. Cell Biol., 94, 71, 10.1016/j.ejcb.2014.12.003 Donetti, 2016, Interleukin 22 early affects keratinocyte differentiation, but not proliferation, in a three-dimensional model of normal human skin, Exp. Cell Res., 345, 247, 10.1016/j.yexcr.2016.05.004 Chiricozzi, 2017, Relevance of in vitro 3-D skin models in dissecting cytokine contribution to psoriasis pathogenesis, Histol. Histopathol. Gutowska-Owsiak, 2011, IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion, Exp. Dermatol., 21, 104, 10.1111/j.1600-0625.2011.01412.x Kim, 2011, TNF-α downregulates filaggrin and loricrin through c-Jun N-terminal kinase: role for TNF-α antagonists to improve skin barrier, J. Investig. Dermatol., 131, 1272, 10.1038/jid.2011.24 Seung, 2007, Comparison of expression of heat shock protein, Toll-like receptors 2 and 4, and T-cell receptor γδ in plaque and guttate psoriasis, J. Cutan. Pathol., 34, 903, 10.1111/j.1600-0560.2007.00756.x Begon, 2007, Expression, subcellular localization and cytokinic modulation of Toll-like receptors (TLRs) in normal human keratinocytes: TLR2 up-regulation in psoriatic skin, Eur. J. Dermatol., 17, 497 Baker, 2002, Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis, Br. J. Dermatol., 148, 670, 10.1046/j.1365-2133.2003.05287.x Patel, 2011, Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and mechanism, Br. J. Dermatol., 164, 670 Miller, 2005, TGF-alpha regulates TLR expression and function on epidermal keratinocytes, J. Immunol., 174, 6137, 10.4049/jimmunol.174.10.6137 Balak, 2017, IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis, Clin. Immunol., 174, 63, 10.1016/j.clim.2016.09.015 Connolly, 2012, New developments in Toll-like receptor targeted therapeutics, Curr. Opin. Pharmacol., 12, 510, 10.1016/j.coph.2012.06.002